Medexus Pharmaceuticals, Inc. (MDP) Stock Analysis | Price, Returns, Financials & Key Metrics

Mojo Score Change: Medexus Pharmaceuticals, Inc. has changed its score on 26 Nov 2025. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

35.57 k

Shareholding (Dec 2024)

FII

0.04%

Held by 1 FIIs

DII

99.96%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

NET PROFIT(Q) At CAD 1.39 MM has Fallen at -60.51%
ROCE(HY) Lowest at 1.88%
INVENTORY TURNOVER RATIO(HY) Lowest at 1.45%

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 92 Million (Micro Cap)

P/E

20.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.24

Return on Equity

6.27%

Price to Book

1.28

Revenue and Profits:

Net Sales:

34 Million

(Quarterly Results - Jun 2025)

Net Profit:

1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-10.16%

6 Months

-5.52%

1 Year

-5.19%

2 Years

71.25%

3 Years

25.11%

4 Years

0.0%

5 Years

0.0%

Medexus Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Medexus Pharmaceuticals Adjusts Valuation Amid Mixed Technical Indicators and Market Outlook

Medexus Pharmaceuticals, Inc. has undergone a recent evaluation adjustment, shifting its valuation grade from very expensive to fair. This change reflects updated financial metrics and technical indicators, indicating a reassessment of the stock's standing within the competitive pharmaceutical sector. The company's financial ratios provide further insights into its structure.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

14.67%

EBIT Growth (5y)

56.33%

EBIT to Interest (avg)

0.69

Debt to EBITDA (avg)

3.02

Net Debt to Equity (avg)

0.25

Sales to Capital Employed (avg)

1.33

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.04%

ROCE (avg)

10.66%

ROE (avg)

4.69%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.24

EV to EBIT

9.84

EV to EBITDA

4.79

EV to Capital Employed

1.20

EV to Sales

0.72

PEG Ratio

Dividend Yield

ROCE (Latest)

12.15%

ROE (Latest)

6.27%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Sideways

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -8.58% vs -12.03% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -74.07% vs 200.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "34.10",
          "val2": "37.30",
          "chgp": "-8.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.50",
          "val2": "7.40",
          "chgp": "-39.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "1.90",
          "chgp": "-42.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.80",
          "val2": "-0.80",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.70",
          "val2": "2.70",
          "chgp": "-74.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.50%",
          "val2": "145.70%",
          "chgp": "-11.12%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -1.18% vs 6.64% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 1,133.33% vs -118.75% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "150.70",
          "val2": "152.50",
          "chgp": "-1.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "25.30",
          "val2": "25.10",
          "chgp": "0.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.90",
          "val2": "14.30",
          "chgp": "-44.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.90",
          "val2": "-2.60",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.10",
          "val2": "-0.30",
          "chgp": "1,133.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "101.80%",
          "val2": "113.10%",
          "chgp": "-1.13%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

34.10

37.30

-8.58%

Operating Profit (PBDIT) excl Other Income

4.50

7.40

-39.19%

Interest

1.10

1.90

-42.11%

Exceptional Items

-0.80

Consolidate Net Profit

0.70

2.70

-74.07%

Operating Profit Margin (Excl OI)

34.50%

145.70%

-11.12%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -8.58% vs -12.03% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -74.07% vs 200.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

150.70

152.50

-1.18%

Operating Profit (PBDIT) excl Other Income

25.30

25.10

0.80%

Interest

7.90

14.30

-44.76%

Exceptional Items

-3.90

-2.60

-50.00%

Consolidate Net Profit

3.10

-0.30

1,133.33%

Operating Profit Margin (Excl OI)

101.80%

113.10%

-1.13%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is -1.18% vs 6.64% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 1,133.33% vs -118.75% in Mar 2024

All Annual Results

Company CV

About Medexus Pharmaceuticals, Inc.

Medexus Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc, is a Canada-based company engaged in pharmaceutical business sector. The Company is a North American focused, specialty pharmaceutical business that operates through three segments: Medac Pharma USA, a fully integrated commercial infrastructure focused on auto-immune diseases in the United States; Medexus Pharma Canada, a fully integrated commercial infrastructure focused on auto-immune disease and pediatric diseases in Canada; and a Business Development function, which works to maintain its product pipeline. The Company's flag products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an allergy medication. The Company provides products for the healthcare professionals and patients.

Company Coordinates

Company Details

225-1 du Commerce Pl , VERDUN QC : H3E 1A2

Tel: 1 514 76226261 905 3303275

https://www.medexusinc.com/

Registrar Details

Medexus Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Medexus Pharmaceuticals Adjusts Valuation Amid Mixed Technical Indicators and Market Outlook

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Mar'25

About Medexus Pharmaceuticals, Inc.

Company Coordinates